A multicenter, open-label, phase II study of PGG beta-glucan and pembrolizumab in patients (pts) with advanced melanoma (MEL) following progression on treatment with checkpoint inhibitors (CPI) or triple negative breast cancer (TNBC) failing front-line chemotherapy for metastatic disease
Iglesias, Jose Luis, Prathikanti, Radha, Ma, Bo, Mattson, Paulette, Kedrowski, Deb, Lowe, Jamie, Bose, Nandita, Ertelt, Katie E., Ottoson, Nadine, Uhlik, Mark T., Graff, Jeremy, Huhn, Richard Dale, Chisamore, Michael Jon
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Effect of imprime PGG on innate immune-activating pharmacodynamic changes in a phase I clinical study in healthy human volunteers
Bose, Nandita, Ottoson, Nadine, Harrison, Ben, Lowe, Jamie R., Matson, Mark, Qiu, Xiaohong, Bykowski Jonas, Adria, Rathmann, Blaine, Kangas, Takashi, Wurst, Lindsay R., Chan, Anissa S.H., Fraser, Kathryn, Walsh, Richard, Ertelt, Katie E., Leonardo, Steven, Fulton, Ross, Gorden, Keith, Uhlik, Mark, Graff, Jeremy, Huhn, Richard Dale
Published in Journal of clinical oncology (01.03.2017)
Published in Journal of clinical oncology (01.03.2017)
Get full text
Journal Article
Endogenous anti-β-glucan antibodies as a potential predictive biomarker for clinical response to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients
Bose, Nandita, Antonysamy, Mary, Patchen, Myra Louise, Lowe, Jamie R., Mattson, Paulette, Gargano, Michele Anne, Gorden, Keith, Leonardo, Steven, Walsh, Richard, Qui, Xiaohong, Ottoson, Nadine, Ertelt, Katie E., Wurst, Lindsay R., McMurray, Diane, Chan, Anissa S.H., Jonas, Adria, Huhn, Richard Dale, Thomas, Michael, Sadjadian, Parvis, Schneller, Folker
Published in Journal of clinical oncology (20.05.2014)
Published in Journal of clinical oncology (20.05.2014)
Get full text
Journal Article